Phase 2 Study

Advancing Care for Solid Tumors

A Study of Disitamab Vedotin With Other Anticancer Drugs

If you or a loved one are facing advanced breast or gastric cancer, you may be eligible to participate in a clinical study evaluating an investigational approach targeting HER2. Discover if this path is right for you.

See If You Qualify Learn How It Works

Understanding the Disitamab Vedotin Trial

Evaluating new combination therapies for advanced solid tumors.

The Purpose of This Study

This clinical trial is evaluating an investigational treatment combination for participants with advanced or metastatic solid tumors. Specifically, the study focuses on breast cancer or gastric cancer where the tumors have spread to other parts of the body and are harder to treat.

Focusing on HER2

Participants in this study must have tumors that express HER2. The presence of HER2 can cause cancer to grow more quickly or spread faster. Currently, there are limited treatment options for patients with advanced solid tumors expressing HER2, making this research critical.

How the Treatment Works

Investigational DrugUses disitamab vedotin (DV), an antibody drug conjugate (ADC) designed to stick to and eliminate cancer cells.
Combination TherapyDV is paired with tucatinib (TUKYSA®), a drug already approved to treat certain cancers in multiple countries.
Careful EvaluationThe study team will closely monitor how safe and effective this combination is, while documenting any side effects.

Study Participation Overview

- Understanding the care, monitoring, and research contributions involved in this trial for advanced solid tumors.

Study Medication

Participants will receive the investigational drug disitamab vedotin (DV) and tucatinib at no cost during the course of the clinical trial.

Health Monitoring

Receive regular health evaluations and medical exams from a dedicated healthcare team to closely monitor your safety and well-being.

Advancing Research

Contribute to vital medical research that may help future patients with HER2-expressing breast and gastric cancers.

Frequently Asked Questions

We understand that participating in a clinical trial is a significant decision. Here are answers to common questions to help you feel informed and confident about the Disitamab Vedotin study.

What is a clinical trial and is it safe?

A clinical trial is a research study that tests how well new medical approaches work in people. Safety is our highest priority. This study follows strict protocols and is closely monitored by medical professionals and independent review boards to protect your well-being throughout the process.

How long will I be in the study?

Your time in the study will depend on how your cancer responds to the treatment (disitamab vedotin and tucatinib) and how well you tolerate it. The study team will provide a detailed timeline during your initial consultation.

What are the possible risks and side effects?

Like all medical treatments, experimental drugs may cause side effects. A side effect is anything a drug does to the body besides treating the disease. Our medical team will thoroughly discuss all known risks with you before you decide to participate, and you will be closely monitored.

Will my information be kept confidential?

Yes. Your privacy is strictly protected. All personal and medical information collected during the study is kept confidential and stored securely in compliance with strict healthcare privacy laws.

Can I leave the study if I change my mind?

Absolutely. Participation is entirely voluntary. You have the right to withdraw from the study at any time, for any reason, without any penalty or loss of your regular medical care.

Will I receive the actual medication or a placebo?

In this specific phase of the study, all participants will receive the active study drugs (disitamab vedotin and tucatinib). There is no placebo used in this dose optimization phase.

What happens after the study ends?

After your participation concludes, the study team will continue to monitor your health for a specified follow-up period. Your regular doctor will be kept informed to ensure a smooth transition back to your standard care.